please refer attached pdf
Awaiting price reaction for this filing.
Ind-Swift Ltd has received a three-year renewal of approval from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) for its 100% Export Oriented Unit (Global Business Unit) located at Jawaharpur, Dera Bassi, Punjab. The renewal follows an assessment by MHRA of the company's quality metrics and quality systems at the facility. As a 100% EOU, this unit's entire output is meant for exports, and the MHRA clearance is essential for supplying pharmaceutical products to the UK and other regulated international markets. No financial details or revenue figures were disclosed in this filing. The intimation was made under SEBI's Listing Obligations and Disclosure Requirements, Regulation 30.
This is positive for shareholders as it ensures uninterrupted export operations from the GBU facility for the next three years. However, since this is a renewal rather than a new approval, the immediate stock price impact is likely to be modest unless the unit is a significant contributor to company revenue.